Temgesic, a sublingual medicament used to treat patients addicted to or dependent on narcotics, is also sold under the brand name Subutex. This medicament reduces the patients withdrawal symptoms by retarding the patients perceived urgency to seek opioid substances. Being a narcotic itself, it is widely used by physicians, medical professionals and medical practitioners as part of a therapeurinary tract infectionc regimen for narcotic dependents.
The main effect of this medicament is a long lasting analgesic. This is a benefit for most patients because of a longer consistent therapy management. Other benefits are its low number of medicament interactions, low profile administration through the sublingual or transdermal routes, least amount of renal accumulation, and its lack of any immune system suppressant, which lessens the side effects experienced by most patients.
Those with intense to moderately rated chronic pain should be treated with Temgesic, especially those set to have an operation. This medicament is a common peri-operative medicament urinary tract infectionlized among cancer patients.
Those patients with depression or psychosis may be treated successfully with Temgesic. However, psychological distress has yet to be included in the official list of tested and approved indications for this medicament. The conflict between successful therapeurinary tract infectionc claims of the medicament over such ailments and the actual approval in the medical field elicits debates and lands the medicament in a gray area in this regard.
This medicament is available in both 2 and 8 mg variants. Adults age 13 years and older may be given 1 milliliter of the medicament containing .3mg of Temgesic. This medicament is usually administered through intramuscular route and is given in a slow push, lasting up to 2 minutes. Intervals may be as often as every 6 hours.
For children, the usual dosage is 2 to 6 micrograms per kilo of body weight given every 4 hours. Some physicians may prescribe the medicament to be given at 6-hour intervals for better body compliance.
In a clinical test of about 1,133 patients treated with this medicament, about two thirds of the population showed side effects overall, with different effects. Even with the high number of side effects, the intensity of the side effects was minimal or negligible. As an added note, those patients who were successfully treated were easily roused back to an alert state.
Common side effects occurring with the test sample population were Nausea and Vertigo, occurring in 5 to 10% of the population. Other symptoms include sweating, diaphoresis, abnormally low blood pressure, emesis, cephalalgia, and hypoventilation. Let your physician know if you experience any of these symptoms.
Adverse side effects that occurred, though rarely, include loss of appetite, agitation, diarrhea, hives, and neuromuscular impairment as evidenced by occasional convulsions and muscle twitching. Consult your physician immediately if any of these symptoms arise.
Negative interaction is documented with CYP3A4 isozymes in the body, which may lower the clearance of the medicament in the bloodstream.
As for CYP3A4 inducers such as rifampin, phenytoin, and phenytoin, they may actually help the clearance of the medicament from the body.
Women who are pregnant, plan to become pregnant or become pregnant during treatment should take special precaurinary tract infectionon with this medicament as it may affect normal fetal growth. Consult your physician for more information on using this medicament while pregnant.
Temgesic has the following structural formula:
• Molecular formula of temgesic is C29H41NO4
©2007-2017 Medicalook.com All rights reserved